

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D. *et al.*
Serial No.: **10/565,713**
Filed: 25 January 2006
Title: SUBSTITUTED 2-AMINOTETRALIN FOR THE TREATMENT OF DEPRESSION
Group Art Unit: 1627
Examiner: U. Ramachandran
Confirmation No.: 7929
Docket No.: **6102-000008/US/NP**
Client Ref.: P/Sche/II/5/03

SUBMITTED ELECTRONICALLY VIA EFS-WEB

8 March 2010

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. §1.114 AND
AMENDMENT D
(INCLUDING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. §1.97(b)(4))

This paper is responsive to a final Office Action dated 7 December 2009 in the above referenced application, in which a shortened statutory period of three months was set for reply. This response is timely filed, and no fee for extension of time is believed to be owed.

Applicant hereby submits a Request for Continued Examination (RCE) under 37 C.F.R. §1.114, accompanied by an amendment and response to all remaining grounds of rejection. Authorization is further provided herewith to charge the RCE fee required under 37 C.F.R. §1.17(e) to Deposit Account No. **08-0750**.

Applicant also submits herein a Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(b)(4).

AMENDMENT UNDER 37 C.F.R. §1.114 (AMENDMENT D)

Amendment of the present application is requested as proposed herein.

Amendments IN THE CLAIMS begin on page 3 of this paper.

REMARKS on the present amendment begin on page 11 of this paper. No increase in total number of claims or in the number of independent claims results from this amendment, and no additional claim fees are believed payable.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT begins on page 24 of this paper.